KB-1222

Nivolumab

×
Please enable JavaScript in your browser to complete this form.
12221
Home » Antibodies » Nivolumab

Background of Nivolumab

PD-1 (programmed death Receptor 1), also known as CD279 (differentiated cluster 279), is an important immunosuppressive molecule. Regulates the immune system and promotes self-tolerance by down-regulating the immune system's response to human cells, as well as by suppressing T cell inflammatory activity. Nivolumab can specifically attach to the PD-1 receptor of T cells and prevent T cell inactivation, thereby blocking the immune escape of cancer cells and improving the immune stem's ability to kill cancer cells.

Specifications

Catalog NumberKB-1222
Antibody NameNivolumab
IsotypeHuman IgG4-S228P, kappa
TargetPD1
Species ReactivityHuman
Host Cell LineEXPI CHO
Purification MethodAffinity purified
Concentration>2 mg/mL
Formulation50 mM sodium citrate,150mM NaCl,pH5.5
Purity>95% by SDS-PAGE and SEC-HPLC
ValidationELISA
Endotoxin Level<0.2 EU/mg as determined by the LAL method
Sterility0.2μm filtered
StorageIt is recommended that the protein should be aliquoted for optimal storage.
Avoid repeated freeze-thaw cycles.
StabilityStable for twelve months from date of receipt when stored at -20°C to -80°C;
Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Kortnye Maureen Smith , Jayesh Desai . Nivolumab for the treatment of colorectal cancer.Expert Rev Anticancer Ther. 2018 Jul;18(7):611-618.
  2. Pengpeng Liu , Xiangyu Pan , Chong Chen , Ting Niu , Xiao Shuai , Jian Wang , Xuelan Chen , Jiazhuo Liu , Yong Guo , Liping Xie , Yu Wu , Yu Liu , Ting Liu .Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults.Blood. 2020 Mar 12;135(11):826-833.
Please enable JavaScript in your browser to complete this form.